Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
Xue
Chu-Biao
CB
Incyte Corporation, Experimental Station E336, Wilmington, DE 19880, USA. cxue@incyte.com
Wang
Anlai
A
Meloni
David
D
Zhang
Ke
K
Kong
Ling
L
Feng
Hao
H
Glenn
Joseph
J
Huang
Taisheng
T
Zhang
Yingxin
Y
Cao
Ganfeng
G
Anand
Rajan
R
Zheng
Changsheng
C
Xia
Michael
M
Han
Qi
Q
Robinson
D J
DJ
Storace
Lou
L
Shao
Lixin
L
Li
Mei
M
Brodmerkel
Carrie M
CM
Covington
Maryanne
M
Scherle
Peggy
P
Diamond
Sharon
S
Yeleswaram
Swamy
S
Vaddi
Kris
K
Newton
Robert
R
Hollis
Greg
G
Friedman
Steven
S
Metcalf
Brian
B
D000284:Administration, Oral; D000818:Animals; D004353:Drug Evaluation, Preclinical; D006801:Humans; D051379:Mice; D011485:Protein Binding; D011759:Pyrrolidines / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D051381:Rats; D054390:Receptors, CCR2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship
C505875:INCB3344; D011759:Pyrrolidines; D054390:Receptors, CCR2